Bausch Health falls after brain dysfunction treatment fails late-stage trials

U.S.-listed shares of drugmaker Bausch Health Companies BHC.TO fall 4.1% to $6.30 premarket

Co says its brain dysfunction treatment failed to meet the main goal in two late-stage trials

Co was testing a new version of its antibiotic, rifaximin, in patients with liver scarring to prevent hepatic encephalopathy, a condition where the liver does not filter toxins, impairing brain function as a result

"We are currently reviewing the full dataset to determine potential new development opportunities," BHC says

Up to stock's last close, BHC declined 13.8% over the past year